Zeneca Files NDA for Arimidex

WILMINGTON, Del--Zeneca Pharmaceuticals has filed a new drug application(NDA) for the use of Arimidex (anastrozole) tablets for the treatmentof advanced breast cancer in postmenopausal women who have progressedfollowing therapy with tamoxifen (Nolvadex).

Arimidex, a nonsteroidal compound, is one of the first of a newclass of selective oral aromatase inhibitors, designed to reducethe production of estrogen. The NDA is based on randomized, controlledtrials involving 764 women with advanced breast cancer, the companysaid.